Latest Articles

Publication Date
All News Scientific
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - markets.businessinsider.com

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) markets.businessinsider.com

Published: June 24, 2026, 11:25 a.m.
Read Full Article
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times

Published: June 24, 2026, 10:48 a.m.
Read Full Article
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - riauone.com

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 riauone.com

Published: June 15, 2026, 12:29 p.m.
Read Full Article
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - The Manila Times

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 The Manila Times

Published: June 14, 2026, 10:21 p.m.
Read Full Article
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - NTB Kommunikasjon

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 NTB Kommunikasjon

Published: June 14, 2026, 10:05 p.m.
Read Full Article
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis - TradingView

ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis TradingView

Published: June 9, 2026, 8:01 p.m.
Read Full Article
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider

Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider

Published: May 15, 2026, 11:33 a.m.
Read Full Article
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment - The American Journal of Managed Care® (AJMC®)

Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment The American Journal of Managed Care® (AJMC®)

Published: May 8, 2026, 4:51 p.m.
Read Full Article
Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment - AJMC

Endometriosis Has a Metabolism Problem, and Targeting It Could Transform Treatment AJMC

Published: May 8, 2026, 4:51 p.m.
Read Full Article
Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers - TradingView

Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers TradingView

Published: May 7, 2026, 12:05 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!